BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-pharmacy-compounding-adcom-july-2026-peptides@catalyst-calendar.local
DTSTAMP:20260720T200547Z
DTSTART:20260723T130000Z
DTEND:20260723T133000Z
SUMMARY:FDA 503A肽类等bulk drug substances复方配制咨询委员会窗口
DESCRIPTION:FDA Pharmacy Compounding Advisory Committee将于2026年7月23日至24日讨论BPC-157、KPV、TB-500、MOTs-C、Semax、Epitalon等bulk drug substances是否纳入503A Bulks List，可能影响复方配制、线上医疗和部分肽类产品监管预期。\\nImpact score: 58\\nExpected: 委员会建议和后续规则制定线索；重点看FDA对肽类复方配制的可接受性、安全性和执行路径。\\nAffected: HIMS(theme\, mixed\, score 78)\; LLY(peer\, mixed\, score 62)\; NVO(peer\, mixed\, score 60)\; XBI(etf\, mixed\, score 52)\; IBB(etf\, mixed\, score 48)\\nSources: FDA advisory committee calendar notice: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nFDA Advisory Committee Calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar\\nFederal Register meeting notice: https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-pharmacy-compounding-adcom-july-2026-peptides
CATEGORIES:policy\,US\,FDA\,compounding\,peptides\,telehealth\,503A\,policy
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA 503A肽类等bulk drug substances复方配制咨询委员会窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA 503A肽类等bulk drug substances复方配制咨询委员会窗口
END:VALARM
END:VEVENT
END:VCALENDAR